Diagnosis and treatment of lupus nephritis flares - An update

Nature Reviews Nephrology

Volumn 8, Issue 12, 2012, Pages 709-717

  Sprangers, Ben ^a   Monahan, Marianne ^b   Appel, Gerald B ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

CLEARANCE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; EVENT FREE SURVIVAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY MALFORMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROSCOPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE FREE SURVIVAL; RECURRENT INFECTION; RELAPSE; REMISSION; RENAL FLARE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE SEDIMENT;

ACUTE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS NEPHRITIS; MORBIDITY; PROGNOSIS; RECURRENCE;

EID: 84870476233     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.220     Document Type: Review

References (86)

1. Appel, G. B. & Jayne, D. Lupus nephritis in Comprehensive Clinical Nephrology (eds Floege, J., Johnson, R. J. & Feehaly, J.) 308-321 (Saunders Elsevier, St. Louis, 2010).
2. Moroni, G., Quaglini, S., Maccario, M., Banfi, G. & Ponticelli, C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 50, 2047-2053 (1996).
3. Moroni, G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22, 2531-2539 (2007).
4. Mosca, M. et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 61, 1502-1509 (2002).
5. Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
6. Moroni, G. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 1, 925-932 (2006).
7. Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011).
8. Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083-2089, (2010).
9. Gordon, C. et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18, 257-263 (2009).
10. Fiehn, C. et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62, 435-439 (2003).
11. Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50, 3934-3940 (2004).
12. Brunner, H. I. et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 54, 2577-2584 (2006).
13. Brunner, H. I. et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 64, 2687-2697 (2012).
14. Rovin, B. H., Song, H., Birmingham, D. J., Hebert, L. A., Yu, C. Y. & Nagaraja, H. N. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467-473 (2005).
15. Zhang, X. et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74, 799-807 (2008).
16. Schwartz, N. et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther. 11, R143 (2009).
17. Satoskar, A. A. et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus 20, 1396-1403 (2011).
18. Fine, D. M. et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 76, 1284-1288 (2009).
19. Birmingham, D. J. et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int. 72, 865-870 (2007).
20. Hebert, L. A. et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin. Pract. 113, c177-c182 (2009).
21. Kraft, S. W., Schwartz, M. M., Korbet, S. M. & Lewis, E. J. Glomerular podocytopathy in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 16, 175-179 (2005).
22. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241-250 (2004).
23. Donadio, J. V. Jr, Holley, K. E., Ferguson, R. H. & Ilstrup, D. M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N. Engl. J. Med. 299, 1151-1155 (1978).
24. Boumpas, D. T. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741-745 (1992).
25. Ciruelo, E., de la, Cruz, J., Lopez, I. & Gomez-Reino, J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 39, 2028-2034 (1996).
26. Gourley, M. F. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125, 549-557 (1996).
27. Ioannidis, J. P. & Moutsopoulos, H. M. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 57, 258-264 (2000).
28. Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156-1162 (2000).
29. Illei, G. G. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46, 995-1002 (2002).
30. Mok, C. C., Ho, C. T., Chan, K. W., Lau, C. S. & Wong, R. W. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. 46, 1003-1013 (2002).
31. Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121-2131 (2002).
32. El Hachmi, M., Jadoul, M., Lefebvre, C., Depresseux, G. & Houssiau, F. A. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 12, 692-696 (2003).
33. Chan, T. M., Tse, K. C., Tang, C. S., Mok, M. Y. & Li, F. K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16, 1076-1084 (2005).
34. Moroni, G. et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol. Dial. Transplant. 21, 1541-1548 (2006).
35. Mok, C. C., Ying, K. Y., Yim, C. W., Ng, W. L. & Wong, W. S. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 18, 1091-1095 (2009).
36. Grootscholten, C. & Berden, J. H. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol. Dial. Transplant. 21, 1465-1469 (2006).
37. Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005).
38. Contreras, G., Tozman, E., Nahar, N. & Metz, D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14 (Suppl. 1), s33-s38 (2005).
39. Sinclair, A. et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16, 972-980 (2007).
40. Chagnac, A. et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J. Clin. Invest. 84, 922-930 (1989).
41. Valeri, A. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin. Nephrol. 42, 71-78 (1994).
42. Hebert, L. A., Dillon, J. J., Middendorf, D. F., Lewis, E. J. & Peter, J. B. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am. J. Kidney Dis. 26, 432-438 (1995).
43. Marto, N., Bertolaccini, M. L., Calabuig, E., Hughes, G. R. & Khamashta, M. A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 444-448 (2005).
44. Matrat, A. et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20, 28-34 (2011).
45. Mak, A., Cheung, B. M., Mok, C. C., Leung, R. & Lau, C. S. Adrenomedullin-a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus. Rheumatology (Oxford) 45, 1266-1272 (2006).
46. Oates, J. C., Shaftman, S. R., Self, S. E. & Gilkeson, G. S. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 58, 263-272 (2008).
47. Mosley, K. et al. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45, 1497-1504 (2006).
48. Chan, R. W. et al. Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology (Oxford) 46, 44-48 (2007).
49. Pitashny, M. et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 56, 1894-1903 (2007).
50. Xuejing, Z. et al. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J. Biomed. Biotechnol. http://dx.doi.org/10.1155/2012/ 359647 (2012).
51. Schwartz, N. et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res. Ther. 11, R143 (2009).
52. Schwartz, N. et al. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27, 242-250 (2006).
53. Feng, X. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2951-2962 (2006).
54. Oates, J. C. et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 68, 2588-2592 (2005).
55. Varghese, S. A. et al. Urine biomarkers predict the cause of glomerular disease. J. Am. Soc. Nephrol. 18, 913-922 (2007).
56. Suzuki, M. et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr. Nephrol. 22, 2047-2057 (2007).
57. Rubinstein, T. et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49, 960-971 (2010).
58. West, C. D. Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus. Am. J. Kidney Dis. 18, 686-688 (1991).
59. ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C. & Kallenberg C. G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 33, 634-643 (1990).
60. Akhter, E., Burlingame, R. W., Seaman, A. L., Magder, L. & Petri, M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20, 1267-1274 (2011).
61. Bootsma, H. et al. Prevention of relapses in systemic lupus erythematosus. Lancet 345, 1595-1599 (1995).
62. Moroni, G. et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am. J. Kidney Dis. 34, 530-539 (1999).
63. Bertsias, G. & Boumpas, D. T. Update on the management of lupus nephritis: let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4, 464-472 (2008).
64. Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121-2131 (2002).
65. Alsuwaida, A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod. Rheumatol. 21, 73-75 (2011).
66. Szeto, C. C. et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47, 1678-1681 (2008).
67. Melander, C. et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 4, 579-587 (2009).
68. Moroni, G. et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann. Rheum. Dis. 71, 1751-1752 (2012).
69. Boletis, J. N. et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol. Dial. Transplant. 24, 2157-2160 (2009).
70. Houssiau, F. A. & Ginzler E. M. Current treatment of lupus nephritis. Lupus 17, 426-430 (2008).
71. Austin, H. A. & Balow J. E. Natural history and treatment of lupus nephritis. Semin. Nephrol. 19, 2-11 (1999).
72. Chen, W. et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21, 944-952 (2012).
73. Uchino, A. et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin. Exp. Rheumatol. 28, 6-12 (2010).
74. Camous, L. et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am. J. Kidney Dis. 52, 346-352 (2008).
75. Nguyen, T., Vacek, P. M., O'Neill, P., Colletti, R. B. & Finette, B. A. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 69, 7004-7012 (2009).
76. Anderka, M. T., Lin, A. E., Abuelo, D. N., Mitchell, A. A. & Rasmussen S. A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am. J. Med. Genet. 149A, 1241-1248 (2009).
77. Hill, G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304-316 (2001).
78. Hill, G. S. et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int. 61, 2176-2186 (2002).
79. Baranowska-Daca, E. et al. Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum. Pathol. 32, 1125-1135 (2001).
80. Daugas, E. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 13, 42-52 (2002).
81. Tektonidou, M. G., Sotsiou, F., Nakopoulou, L., Vlachoyiannopoulos, P. G. & Moutsopoulos H. M. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 50, 2569-2579 (2004).
82. Cheunsuchon, B., Rungkaew, P., Chawanasuntorapoj, R., Pattaragarn, A. & Parichatikanond, P. Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology (Carlton) 12, 474-480 (2007).
83. Bajaj, S. et al. Serial renal biopsy in systemic lupus erythematosus. J. Rheumatol. 27, 2822-2826 (2000).
84. Gunnarsson, I. et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum C1q and albuminuria. J. Rheumatol. 29, 693-699 (2002).
85. Tam, L. S., Li, E. K., Lai, F. M., Chan, Y. K. & Szeto, C. C. Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus 12, 665-671 (2003).
86. Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I. & Estes, D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am. J. Med. 83, 877-885 (1987).